On the catch-up time method for analyzing cancer screening trials.

In randomized cancer screening trials, the ratio of the mortality rate for the screened group to that for the control group is typically not constant as a function of years from randomization. This is due to an initial lag effect, but also to a dilution effect that results from the accrual of comparable cases in both groups after the end of the screening period. In order to combat the potential loss of power when applying conventional analysis tools, specifically the logrank test, Aron and Prorok (International Journal of Epidemiology 15, 36-43), have advocated analyzing the mortality experience using only the subcohort of cases ascertained within a given time period. However, it is not clear how to select an appropriate case ascertainment point, since this will depend on aspects of the natural history of the disease process which are poorly identified. Aron and Prorok suggest choosing the case ascertainment point to be the point at which the cumulative number of cases in the control group first becomes equal to that in the intervention group, that is, the "catch-up time." In this paper, we undertake a thorough evaluation of the bias and power properties of the catch-up time method. We base our study on simulated data resembling the Health Insurance Plan of Greater New York study cohort. We consider several models for postdiagnosis survival under the null hypothesis of no screening effect on mortality, and under the alternative hypothesis of an effect of screening. We show that the catch-up method can yield tests with sizeable bias. In the absence of detailed knowledge about the underlying disease process, we suggest some adaptive tests that maintain nominal size but have more attractive power properties than the standard logrank test.

[1]  Ruth Etzioni,et al.  A likelihood ratio test for cancer screening trials. , 1995, Biometrics.

[2]  S G Self,et al.  An adaptive weighted log-rank test with application to cancer prevention and screening trials. , 1991, Biometrics.

[3]  R Brookmeyer,et al.  Reconstruction and future trends of the AIDS epidemic in the United States. , 1991, Science.

[4]  R. Tarone,et al.  Analysis of breast cancer mortality and stage distribution by age for the Health Insurance Plan clinical trial. , 1988, Journal of the National Cancer Institute.

[5]  L. Stitt,et al.  Evaluating the survival of cancer cases detected by screening. , 1987, Statistics in medicine.

[6]  J. Habbema,et al.  Age-specific reduction in breast cancer mortality by screening: an analysis of the results of the Health Insurance Plan of Greater New York study. , 1986, Journal of the National Cancer Institute.

[7]  P. Prorok,et al.  An analysis of the mortality effect in a breast cancer screening study. , 1986, International journal of epidemiology.

[8]  J D Habbema,et al.  The MISCAN simulation program for the evaluation of screening for disease. , 1985, Computer methods and programs in biomedicine.

[9]  N. Day,et al.  Simplified models of screening for chronic disease: estimation procedures from mass screening programmes. , 1984, Biometrics.

[10]  S D Walter,et al.  Estimation of the duration of a pre-clinical disease state using screening data. , 1983, American journal of epidemiology.

[11]  S. Shapiro,et al.  Ten- to fourteen-year effect of screening on breast cancer mortality. , 1982, Journal of the National Cancer Institute.

[12]  J. Wittes,et al.  The Evaluation of Medical Screening Procedures , 1981 .

[13]  D. Clayton A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence , 1978 .

[14]  S. Shapiro,et al.  Evidence on screening for breast cancer from a randomized trial , 1977, Cancer.

[15]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.